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Hepatitis C virus seroprevalence in the
general female population of 9 countries
in Europe, Asia and Africa
Gary M. Clifford1*, Tim Waterboer2, Bolormaa Dondog2, You Lin Qiao3, Dimitri Kordzaia4, Doudja Hammouda5,
Namory Keita6, Nahid Khodakarami7, Syed Ahsan Raza8,9, Ang Tshering Sherpa10, Witold Zatonski11,
Michael Pawlita2, Martyn Plummer1 and Silvia Franceschi1
Abstract
Background: New oral treatments with very high cure rates have the potential to revolutionize global management
of hepatitis C virus (HCV), but population-based data on HCV infection are missing in many low and middle-income
countries (LMIC).
Methods: Between 2004 and 2009, dried blood spots were collected from age-stratified female population samples of
9 countries: China, Mongolia, Poland, Guinea, Nepal, Pakistan, Algeria, Georgia and Iran. HCV antibodies were detected
by a multiplex serology assay using bead-based technology.
Results: Crude HCV prevalence ranged from 17.4% in Mongolia to 0.0% in Iran. In a pooled model adjusted by age
and country, in which associations with risk factors were not statistically heterogeneous across countries, the only
significant determinants of HCV positivity were age (prevalence ratio for ≥45 versus <35 years = 2.84, 95%CI 2.18-3.71)
and parity (parous versus nulliparous = 1.73, 95%CI 1.02-2.93). Statistically significant increases in HCV positivity by age,
but not parity, were seen in each of the three countries with the highest number of HCV infections: Mongolia, Pakistan,
China. There were no associations with sexual partners nor HPV infection. HCV prevalence in women aged ≥45 years
correlated well with recent estimates of female HCV-related liver cancer incidence, with the slight exception of
Pakistan, which showed a higher HCV prevalence (5.2%) than expected.
Conclusions: HCV prevalence varies enormously in women worldwide. Medical interventions/hospitalizations linked
to childbirth may have represented a route of HCV transmission, but not sexual intercourse. Combining dried blood
spot collection with high-throughput HCV assays can facilitate seroepidemiological studies in LMIC where data is
otherwise scarce.
Keywords: Hepatitis C virus, Epidemiology, Serology, Liver cancer
Background
About 180 million people, some 3% of the world’s popu-
lation, are estimated to have been exposed to hepatitis C
virus (HCV) [1–3]. Of these, 130–150 million (~80%)
are chronically HCV infected and at risk for develop-
ment of hepatitis-C related liver cirrhosis or cancer,
which kill approximately 700,000 people each year [4].
Although new HCV treatments offering very high cure
rates with short durations and few side effects have the
potential to drastically reduce HCV-related mortality,
access to diagnosis and expensive treatment remain low,
so that the number of people living with HCV is actually
reported to be increasing [1].
In 2016, the World Health Assembly adopted a strat-
egy to eliminate viral hepatitis as a major public health
threat by 2030, noting that national data on hepatitis
virus infection are often lacking [5]. In addition, available
HCV surveys often over-represent low-risk groups, par-
ticularly younger low-risk persons (e.g. pregnant women
and blood donors), whereas HCV prevalence is known
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to increase steadily with age owing to the combination
of accumulating risk of exposure and a high probability
of infection becoming chronic [6].
Common routes of HCV infection are unsafe injec-
tions, inadequate sterilization of medical equipment, and
the transfusion of unscreened blood and blood products
that have been common in high-income countries till
the 1980s and also more recently in low- and medium-
income countries (LMIC). Because these practices are
largely specific to a given country’s medical system,
HCV prevalence and the timing of infection spread may
differ between bordering countries [2], and national level
data on HCV infection is required to inform public
health decisions.
Hence, we exploited a series of standardized seroepi-
demiological surveys in order to describe HCV preva-
lence and risk factors among the general female
population of a heterogeneous range of countries around
the world. HCV seropositivity was determined using a
high throughput assay that has been shown to provide
an accurate and cost-effective tool for assessment of
HCV antibodies in large epidemiologic studies [7], and
we went on to compare country-specific HCV preva-
lence with recently generated country-specific estimates
of HCV-related liver cancer incidence.
Methods
Population
Between 2004 and 2009, studies were undertaken in 11
areas in 9 countries with the primary aim to estimate
the prevalence of genital human papillomavirus virus
(HPV) infection, according to a similar protocol
developed and co-ordinated by the International Agency
for Research on Cancer (IARC). Population sampling
methods have been previously described for the individ-
ual study centres: Shanxi, China [8]; Shenyang, China
[9]; Shenzhen, China [10]; Ulaanbaatar, Mongolia [11];
Warsaw, Poland [12]; Conakry, Guinea [13]; Bharatpur,
Nepal [14]; Karachi, Pakistan [15]; Zeralda, Algeria [16];
Tbilisi, Georgia [17]; and Tehran, Iran [18]. In each area,
an attempt was made to obtain an age-stratified
population-based sample that included at least 100
women in each 5-year age group, from 15-19 up to 65
years and older. The number of included women is
sometimes higher than that in the original reports due
to relaxing of selection criteria for adequacy of genital
specimens. Data from Mongolia have been previously re-
ported in validation studies of the present HCV sero-
logical assay [7, 19]. Trained interviewers administered a
face-to-face questionnaire that included information on
sociodemographic characteristics, sexual behaviour, re-
productive and contraceptive history, and smoking
habits. All participants signed informed consent forms
according to the recommendations of the IARC Ethics
Committee, and of the local ethical review committees
in each of the participating countries, which also ap-
proved each of the original studies.
Specimen collection
Each participant had a blood sample collected by veno-
puncture. In Mongolia, this sample was drawn from the
cubital fossa into vacuum containers without anticoagu-
lant [19], whereas in all other areas, samples were ob-
tained by fingerstick. In both instances, full blood was
then immediately applied to DBS (dried blood spot)
filter paper card (Whatman 903 Protein Saver Blood
Collection Cards; Schleicher & Schuell) to entirely fill
five 14.5 mm diameter circles. DBS cards were dried at
room temperature, placed in separate plastic paper zip lock
envelopes containing a silica desiccant, and shipped at am-
bient temperature to the German Cancer Research Center
(DKFZ) in Heidelberg, Germany, and stored at -20°C until
serological analysis.
Study participants were also invited for a pelvic
examination (although a subset, particularly self-
reported virgins, declined) and collection of cervical
exfoliated cells for HPV DNA testing, performed in
the Department of Pathology, VU University Medical
Center, Amsterdam, the Netherlands, according to a
general primer GP5+/6 + –mediated PCR [20].
HCV serology
Antibodies were eluted from DBS cards according to a
previously reported protocol that has been shown to re-
sult in high agreement (>96% for HCV antigens) of sero-
positivity in paired DBS and serum results [19]. In brief,
one punch of 6 mm diameter from each DBS was eluted
in one well of a 96-well plate in 100 μL PBS at 4oC over-
night, and 16 μl of eluate subsequently mixed with 80
μL DBS preincubation buffer.
A multiplex serology assay [19] including antigens
to HCV (strain H77, subtype 1a) Core and NS3 pro-
teins was performed as previously described [7]. In
brief, full-length coding sequences of Core and NS3
were expressed as double fusion proteins with an N-
terminal-GST and a C-terminal tag epitope derived
from the large T-antigen of SV40 in E. coli. Fusion
proteins were loaded and affinity-purified on glutathione-
casein coupled spectrally distinct fluorescence-labeled
polystyrene beads (SeroMap; Luminex). DBS eluates were
incubated with pooled antigen loaded bead sets. Bound
antibodies were quantified with biotinylated goat anti-
human IgA, IgM, IgG (Dianova), and R-phycoerythrin–la-
beled streptavidin in a Luminex 100 analyzer as the me-
dian R-phycoerythrin fluorescence intensity (MFI) from at
least 100 beads of the same bead set. Antigen-specific MFI
values were calculated as previously described [21].
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DBS-specific cut-off values for HCV Core (MFI ≥ 967)
and NS3 (MFI ≥ 310) were defined as the mean MFI plus
three SDs from 235 reference sera that tested negative
by a commercial HCV antibody screening assay [19].
Women that were positive for both Core and NS3
proteins were defined as being HCV-positive. In an
evaluation against a set of 432 reference sera, this cut-off
has been proven to perform similarly, in a single step, to
a commercial HCV antibody screening assay (MEIA)
followed by RNA confirmation (98% sensitivity, 99%
specificity) [7].
When a subset of 2,988 DBS samples from 8 study
areas were re-tested on a second occasion to evaluate
assay reproducibility, 2,982 (99.8%) were concordantly
classified (2,940 HCV-negative, 42 HCV-positive).
Statistical analyses
HPV prevalence was standardized by age using the
world standard population (in 5-year age groups from
15-19 to 60-65 years) as a reference [22]. Prevalence ra-
tios (PR) for HCV seropositivity and corresponding 95%
confidence intervals (CI) were calculated using uncondi-
tional logistic regression adjusted for age (5-year groups)
and study area. Heterogeneity of PRs between study
areas was tested by calculating the difference between
the log likelihood of the model that considered the inter-
action term between the areas and risk factor of interest
and the log likelihood of the model that included the ex-
posure only, and comparing it to the chi-squared distri-
bution with degrees of freedom equal to the number of
areas minus one.
Country-specific estimates of HCV-related liver cancer
incidence in women were extracted from Plummer et al,
Lancet Global Health, 2016 [23], derived by combining
country-specific estimates of HCV attributable fraction
in liver cancer with Globocan 2012 [24] estimates of fe-
male liver cancer incidence.
Results
HCV serology results were obtained for a total of 12,204
women, with study-specific sample sizes varying from
1,516 for Shenzhen, China, down to 892 for Iran
(Table 1). Overall median age was 34 years, varying from
30 to 38 years by study center (Table 1). A total of 274
women (2.2%) were HCV-positive. Crude HCV preva-
lence ranged from 17.4% in Mongolia down to 0.0% in
Iran (Table 1). Age-standardization reduced HCV preva-
lence estimates (by increasing the relative weight of
younger age groups, who were less often HCV-positive),
but did not change relative differences in HCV positivity
between centers.
Table 2 shows the relationship of selected characteris-
tics of study women with HCV positivity. In a model ad-
justed by age and study area, as appropriate, the only
significant determinants of HCV positivity were age
group (PR for ≥45 versus <35 years = 2.84, 95% CI 2.18-
3.71) and parity (PR for parous versus nulliparous =1.73,
95% CI 1.02-2.93). However, no risk trend was found by
number of births. Associations of HCV positivity with
risk factors were not statistically heterogeneous across
study areas (p values for heterogeneity = 0.17, 0.88, 0.59
and 0.25 for age, sexual partners, parity and induced
abortion, respectively).
Findings by age group and parity are also shown
separately for Mongolia, Pakistan and China (the three
countries with the highest number of HCV-positive
women) in Table 3. Statistically significant increases in
HCV positivity by age were seen in each of the three
Table 1 HCV prevalence by study center
HCV prevalence
Crude Age-standardizeda
Geographical area Median age N tested N pos % 95% CI % 95% CI
Mongolia, Ulaanbaatar 35 1,075 187 17.4 15.2-19.2 10.9 3.3-18.6
Pakistan, Karachi 35 963 31 3.2 2.2-4.5 1.7 0.5-2.9
Georgia, Tbilisi 33 1,431 17 1.2 0.7-1.9 0.7 0.0-1.4
Guinea, Conakry 30 1,253 11 0.9 0.4-1.6 0.5 0.0-1.4
Poland, Warsaw 37 909 7 0.8 0.3-1.6 0.3 0.0-0.9
China, Shenyang 34 989 6 0.6 0.2-1.3 0.4 0.0-1.7
China, Shanxi 36 940 6 0.6 0.2-1.4 0.3 0.0-0.8
China, Shenzhen 30 1,516 6 0.4 0.1-0.9 0.3 0.0-0.6
Nepal, Bharatpur 33 1,061 2 0.2 0.0-0.7 0.2 0.0-0.8
Algeria, Zeralda 36 1,135 1 0.1 0.0-0.5 0.1 0.0-0.2
Iran, Tehran 38 892 0 0 0.0-0.4 0.0 0.0-0.4
Total 34 12,164 274 2.2 2.0-2.5 1.4 1.0-1.83
aStandardized to world population in CI5 [22]
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countries, but the rise between women <35 to those 35-
44 years of age was especially steep in Pakistan. In-
creases in HCV positivity in parous women were only
observed in Mongolia and Pakistan and did not meet
statistical significance (Table 3).
Age-specific HCV prevalence estimates are shown by
study country in Fig. 1, in order of highest to lowest HCV
prevalence among women aged ≥45 years, and are plotted
against country-specific estimates of female HCV-related
liver cancer incidence rates. Age-specific increases in
HCV prevalence were observable in Mongolia, Pakistan,
Guinea, Poland and China. HCV prevalence estimates in
women aged ≥45 years correlated well with female HCV-
related liver cancer incidence rates, ranging between the
extremes of Mongolia (28.4% HCV prevalence versus 20.9
cases of HCV liver cancer per 100,000 women) and Iran
(0.0% HCV prevalence versus 0.2 cases of HCV liver can-
cer per 100,000 women). The only slight exception to this
Table 2 Prevalence ratios (PR) for HCV positivity and corresponding 95% confidence intervals (CI) according to selected women’s
characteristics
Risk factor N tested HCV positive
N (%)
Adjusted PRa 95% CI
Age 12,164
<35 6,249 79 (1.3) 1 -
35-44 2,894 78 (2.7) 1.86 1.39-2.50
≥45 3,021 117 (3.9) 2.84 2.18-3.71
χ12 for trend p < 0.001
Education level 12,156
None 1,713 24 (1.4) 1 -
Primary 1,552 21 (1.3) 0.96 0.52-1.77
Secondary and higher 8,891 229 (2.6) 0.86 0.46-1.60
Lifetime number of sexual partnersb 10,926
0 1,086 1 (0.1) 0.21 0.03-1.55
1 7,513 146 (1.9) 1 -
2 1,305 60 (4.6) 1.12 0.84-1.49
3+ 1,022 65 (6.4) 1.08 0.81-1.44
χ1
2 for trend p = 0.367
Number of births (parity) 11,199
Nulliparous 2,207 21 (0.9) 1 -
1 3,228 55 (1.7) 1.68d 0.98-2.90
2 2,644 75 (2.8) 1.81d 1.01-3.26
3+ 3,120 119 (3.8) 1.84d 1.01-3.38
χ12 for trend p = 0.171
Induced abortionc 9,166
0 5,433 95 (1.7) 1 -
1 1,750 46 (2.6) 0.97 0.69-1.37
2+ 1,983 112 (5.6) 1.24 0.93-1.66
χ12 for trend p = 0.121
Smoking status 12,153
Never 10,860 235 (2.2) 1 -
Ever 1,293 38 (2.9) 1.21 0.88-1.66
HPV DNA-positive 9,984
No 8,264 183 (2.2) 1 -
Yes 1,720 65 (3.8) 1.04 0.80-1.36
aAdjusted for age (5-year groups) and geographical area, as appropriate
bAlgeria excluded because of missing data
cAlgeria and Guinea excluded because of missing data
dCombined PR for ≥ 1 versus 0 = 1.73 (1.02-2.93)
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correlation was Pakistan, which showed a high HCV
prevalence (5.2%) in comparison to a relatively low esti-
mate of female HCV-related liver cancer (1.3 cases per
100,000 women).
Discussion
Benefiting from a standardized population-based sam-
pling protocol and a validated serological assay, we
describe important variation in HCV seroprevalence in
women around the world and robustly confirm the
absence of a sexual transmission route for HCV infec-
tion. Crude population-based HCV prevalence ranged
from 17% in Mongolia down to 0% in Iran and corre-
lated with country-specific estimates of female HCV-
related liver cancer incidence, which are also highest in
Mongolia (20.9 per 100,000 women) and lowest in Iran
(0.2 per 100,000 women) in women aged ≥45 years.
Furthermore, when available, our estimates were com-
patible with previous population-based estimates of
HCV prevalence in the evaluated countries.
Table 3 HCV positivity by age and number of births, separately for Mongolia, Pakistan and China
Mongolia Pakistan China
Risk factor N tested HCV positive
N (%)
Adjusted PRa
and 95% CI
N tested HCV positive
N (%)
Adjusted PRa
and 95% CI
N tested HCV positive
N (%)
Adjusted PRa
and 95% CI
Age 1,075 963 3,445
<35 511 55 (10.8) 1 479 7 (1.5) 1 1,915 5 (0.3) 1
35-44 289 54 (18.7) 1.74 (1.23-2.45) 254 12 (4.7) 3.23 (1.29-8.11) 755 4 (0.5) 2.03 (0.55-7.54)
≥45 275 78 (28.4) 2.63 (1.93-3.60) 230 12 (5.2) 3.57 (1.42-8.95) 775 9 (1.2) 4.45 (1.49-13.2)
χ12 for trend p < 0.001 p = 0.005 p = 0.007
Number of births 1,056 955 3,225
0 228 16 (7.0) 1 136 1 (0.7) 1 942 2 (0.2) 1
≥1 828 169 (20.4) 1.62 (0.86-3.04) 819 30 (3.7) 3.06 (0.39-24.1) 2,283 16 (0.7) 0.48 (0.06-3.82)
aAdjusted for age (5 years groups), as appropriate
Fig. 1 Correlation of age-specific HCV prevalence with HCV-related liver cancer incidence in women ≥45 years
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The extreme HCV prevalence in Mongolia was ex-
pected and has been previously described [7]. Indeed,
Mongolia has the highest burden of HCV-related liver
cancer in the world [23], driven by a long-lasting epi-
demic due to iatrogenic transmission of HCV through
mass vaccination campaigns (e.g. smallpox, polio [25],
blood transfusions [26, 27]) and extensive use of injected
treatments [28]. At the lower extreme, we confirm an
anti-HCV prevalence of less than 1% reported from a
wide-range of other population-based studies in Iran
[29], where a low fraction of liver cancers are estimated
to be attributable to HCV [30].
The relatively high HCV prevalence found in Karachi,
Pakistan (~5% in women aged 45+ years) is similar to
that in previous large population-based surveys in Kara-
chi [31, 32] and nationwide in Pakistan [33]. Indeed,
HCV was reported to be the predominant cause of liver
cancer in Pakistan [34, 35]. Given this high HCV preva-
lence, however, current estimates of HCV-related liver
cancer incidence in Pakistani women are lower than ex-
pected. This may be due to limitations in liver cancer in-
cidence data for Pakistan [24], or to a more recent
iatrogenic spread of the virus compared to, for instance,
Mongolia. Indeed the proportion of HCV-positive hepa-
tocellular carcinoma is still increasing in Pakistan [34].
HCV prevalence estimates were highly consistent
across the three Chinese sites (0.4-0.6%) and compatible
with estimates of 0.4-1.0% in large population-based sur-
veys of women performed since 2006 [36–39]. HCV
prevalence is especially low below age 45. Thus, im-
provements in transfusion practices implemented in
China in the mid-1990s, notably prohibition of paid
donations of plasma and blood that were associated
with mass transmission of HCV and HIV, appear to
have largely controlled the HCV epidemic. Indeed,
population-based HCV prevalence [36], and proportion of
liver cancer attributed to HCV [34], appears to be rela-
tively low and decreasing over time in China.
HCV prevalence in women in Tbilisi, Georgia (1.3%) is
compatible with that from a previous population-based
survey in which the vast majority of HCV infections in
Tbilisi were observed to occur among male intravenous
drug users [40]. Indeed, increasing intravenous drug use
is feared to be an important source of recent HCV
transmission in many former Soviet republics [41]. Esti-
mates of 0.8% HCV prevalence in Warsaw, Poland are
similar to that in a nationwide study of 42,274 women
(0.8% [42]), and with that modelled from meta-analytical
data [43].
No population-based data are available for Algeria, but
our HCV prevalence estimates (0.1%) compare well to
the 0.2% and 0.6% reported among 1,000 [44] and 3,044
[45] pregnant women, respectively. This would suggest
Algeria to have an HCV prevalence similar to its
neighbors Morocco and Tunisia [46], and much lower
than in Egypt [2], for which much more population-
based data is available.
No population-based data are available for Nepal, but
our HCV prevalence estimate of 0.2% compares well to
the 0.1% reported among 2,007 female blood donors
[47], suggesting that Nepal has largely escaped an epi-
demic of HCV to date.
Lastly, this study provides the first report on HCV in-
fection in Guinea, for which the 0.9% HCV prevalence is
lower than previous regional estimates for West sub-
Saharan Africa (2.8% [1] and 5.3% [2]), which are none-
theless very sensitive to the lack of relevant data from
this region of the world. Lower HCV prevalence among
women aged under 45 years in Guinea may represent a
cohort effect of reduced HCV transmission in younger
generations.
HCV infection increased with age in most countries,
presumably due to accumulating risk of exposure. This
confirms steady increases up to the age of 60 years re-
ported in a meta-analysis of age-specific HCV infection
from Mongolia and Poland [43], and in large studies in
China [36–39].
Given the orientation of the surveys towards studying
HPV, questionnaires did not include variables that would
be useful to studying specific iatrogenic transmission
routes. Nevertheless, to our knowledge, this is the first
study to suggest the existence of a possible association
between HCV infection and parity, which persisted even
after adjustment for center and age, which may repre-
sent a risk of HCV transmission by medical interven-
tions/hospitalizations linked to childbirth. On the other
hand, we were able to robustly confirm the absence of
sexual transmission of HCV in the general female popu-
lation, through the null association with number of sex-
ual partners, and presence of cervical HPV infection, as
proxies of sexual intercourse.
Our data arises entirely from females in selected
towns, and may not be representative of males or
other areas in the same country. In most populations
around the world, HCV prevalence in females has
been estimated to be similar or lower than that in
males [43]. However, at least Mongolia [43] and
China [38] may represent exceptions to this rule. In
any case, we propose that our population-based sam-
pling procedures provide a more representative pic-
ture than studies limited to typically young pregnant
women or blood donors.
HCV genotypes are known to vary between the differ-
ent worldwide regions represented by this study. Never-
theless, the cross-reactivity of serological assays for NS3
and Core proteins of genotypes 1a, 1b and 2a does not
suggest that their performance should be affected by the
existence of HCV serotypes [7]. Furthermore, the assay
Clifford et al. Infectious Agents and Cancer  (2017) 12:9 Page 6 of 8
was shown to be highly reproducible when a large subset
of samples were re-tested on a second occasion, and has
been well-validated against commercial HCV tests [7]
and for use with dried blood spots [19]. Taken together,
we believe that this protocol represents a useful model
for obtaining HCV prevalence data from low- and
middle-income settings where data is scarce, for both
men and women alike. Indeed, DBS do not require
blood centrifugation and allow storage and shipment at
ambient temperature, thus facilitating field work for ser-
oepidemiological studies in environments with limited
technical infrastructure, and the research serological
assay is both high-throughput and cost-effective.
Conclusions
HCV prevalence varied enormously across the female
populations represented in our study. Medical interven-
tions/hospitalizations linked to childbirth may have rep-
resented a route of HCV transmission, at least in some
settings, but not sexual intercourse. Combining dried
blood spot collection with high-throughput HCV assays
can facilitate seroepidemiological studies in LMIC where
data is otherwise scarce. Indeed, the availability of
population-based HCV estimates is going to become in-
creasingly relevant in the next years, as countries con-
sider the cost and public health priority of going beyond
the prevention of HCV transmission by ensuring safety
of medical interventions, towards screen-and-treat ap-
proaches that can benefit from a new generation of
highly performant oral HCV treatment regimens [5].
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